The effects of raloxifene on endothelial function and Inflammation in Postmenopausal women: A Meta-analysis of randomized controlled trials

Kang, Fuli; Zou, Qi; Huang, Jiazhen

doi:10.1016/j.exger.2021.111682

Cited by 4 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 381 SREMs are structurally diverse compounds that act either as ER agonists or antagonists by interacting with ERs in target organs. Those approved or under clinical trials that have shown beneficial effects on BMD in postmenopausal women with osteoporosis (e.g., raloxifene, 382 , 383 lasofoxifene, 384 , 385 bazedoxifene 386 ) are ER agonists in bone. 387 , 388 …”

Section: Strategies and Challenges In The Management Of Osteoporosismentioning

confidence: 99%

Insights and implications of sexual dimorphism in osteoporosis

Zhang,

Xie,

Sun

et al. 2024

Bone Res

View full text Add to dashboard Cite

Osteoporosis, a metabolic bone disease characterized by low bone mineral density and deterioration of bone microarchitecture, has led to a high risk of fatal osteoporotic fractures worldwide. Accumulating evidence has revealed that sexual dimorphism is a notable feature of osteoporosis, with sex-specific differences in epidemiology and pathogenesis. Specifically, females are more susceptible than males to osteoporosis, while males are more prone to disability or death from the disease. To date, sex chromosome abnormalities and steroid hormones have been proven to contribute greatly to sexual dimorphism in osteoporosis by regulating the functions of bone cells. Understanding the sex-specific differences in osteoporosis and its related complications is essential for improving treatment strategies tailored to women and men. This literature review focuses on the mechanisms underlying sexual dimorphism in osteoporosis, mainly in a population of aging patients, chronic glucocorticoid administration, and diabetes. Moreover, we highlight the implications of sexual dimorphism for developing therapeutics and preventive strategies and screening approaches tailored to women and men. Additionally, the challenges in translating bench research to bedside treatments and future directions to overcome these obstacles will be discussed.

show abstract

Section: Strategies and Challenges In The Management Of Osteoporosismentioning

confidence: 99%

Insights and implications of sexual dimorphism in osteoporosis

Zhang,

Xie,

Sun

et al. 2024

Bone Res

View full text Add to dashboard Cite

show abstract

“…In a recent network Bayesian meta-analysis involving 9 randomized trials ( N =60,732), raloxifene, as compared to other SERMs, was more potent in terms of decreasing risk of invasive breast cancer by as much as 35% [odds ratio (OR) 0.65, 95% confidence interval (CI) 0.48–0.85), while tamoxifen increased the risk for endometrial cancer (OR 2.42, 95% CI 1.10–7.35) [ 33 ]. Raloxifene is also beneficial, relative to placebo, in terms of decreasing vertebral fracture risk, not hip fracture, with reported cardiovascular benefits but with increased risk for thromboembolic events [ 34 , 35 ]. The use of raloxifene, however, is quite low in SA since there are more effective and safer alternatives.…”

Section: Selective Estrogen Receptor Modulators (Serms)mentioning

confidence: 99%

Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society

et al. 2023

View full text Add to dashboard Cite

Summary The Saudi Osteoporosis Society (SOS) has updated its guidelines for the diagnosis and management of osteoporosis in Saudi Arabia (SA), with emphasis on postmenopausal women. This document is relevant to all healthcare professionals in SA involved in the care of patients with osteoporosis and osteoporosis-related fractures. Introduction The SOS launched the first national osteoporosis guidelines in 2015 and spearheaded the Gulf Cooperation Council Countries (GCC) osteoporosis consensus report in 2020 which was under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO). This paper highlights a major update of the guidelines in the SA setting. Methods This guideline is an adaptation of the current guidelines derived from ESCEO, the American Association of Clinical Endocrinologists (AACE), and the GCC osteoporosis consensus report and studies on osteoporosis done in SA. Where accessible, the timeliest systematic review, meta-analysis, and randomized controlled trials were used as evidence. Results The present update includes new recommendations for the assessment of osteoporosis taking into consideration the Saudi model of FRAX for fracture probabilities, appropriate doses for the maintenance of vitamin D status and calcium, the use of representative blood analytes for therapy monitoring, the use of romosozumab and sequential therapy in the pharmacological management strategies, and the establishment of fracture liaison services to prevent secondary fractures. Conclusion This updated guideline is for all healthcare professionals involved in osteoporosis and post-fracture care and management in SA and harmonized the most up-to-date changes in the field based on evidence-based medicine for use in the local setting.

show abstract